EL
ELLXF.US Elixinol Global Ltd
- Market cap
- USD 1.83M
- P/E
- -
- P/B
- 0.42x
- ROE
- -67.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is ELLXF.US undervalued?
Graham numberThe Graham number of Elixinol Global Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Elixinol Global Ltd fundamental analysis
No fundamental analysis for Elixinol Global Ltd yet.
Elixinol Global Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Elixinol Global Ltd
Elixinol Wellness Limited, a holding company, produces and sells human nutrition, human wellness, pet wellness, and superfood ingredients in Australia, the Americas, and internationally. The company offers its products under Hemp Foods Australia, Mt Elephant, The Healthy Chef, Soul Foods, Ananda Equine, and Field Day brands. It distributes its products through grocery, wholesale, and e-commerce channels for white label customers, as well as food, beverage, and beauty manufac…
Full company profileElixinol Global Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Elixinol Global Ltd annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 6.00K | 37.1M | 30.7M | 15.0M | 9.34M | 7.06M | 8.27M | 15.0M | 15.5M | 28.9M |
| Gross Profit | -17.0K | 20.0M | -743K | -9.58M | -6.26M | -3.27M | 3.42M | 5.64M | 752K | 4.86M |
| Operating Income | -2.74M | -978K | -25.8M | -22.1M | -15.6M | -10.0M | -6.46M | -5.11M | -4.97M | -2.44M |
| EBITDA | -2.72M | -389K | -70.8M | -21.9M | -14.2M | -9.28M | -6.81M | -4.09M | -4.11M | -936K |
| Net Income | -2.71M | -860K | -80.6M | -105M | -17.0M | -10.6M | -7.51M | -1.72M | -5.50M | -4.30M |
| EPS | -0.02 | -0.01 | -0.41 | -0.45 | -0.04 | -0.03 | -0.10 | -0.01 | -0.02 | -0.01 |
| Balance Sheet | ||||||||||
| Total Assets | 105M | 154M | 121M | 42.5M | 25.3M | 13.5M | 11.7M | 18.4M | 16.0M | 15.1M |
| Total Liabilities | 5.91M | 9.96M | 9.69M | 6.82M | 6.26M | 4.33M | 5.25M | 8.42M | 8.51M | 8.79M |
| Shareholders' Equity | 99.1M | 144M | 111M | 35.7M | 19.1M | 9.16M | 6.46M | 10.0M | 7.45M | 6.36M |
| Cash & Short-term Investments | 18.8M | 42.9M | 20.2M | 27.7M | 12.6M | 2.86M | 708K | 1.08M | 1.40M | 995K |
| Total Debt | 288K | 250K | 4.63M | 2.74M | 2.72M | 1.84M | 1.26M | 1.94M | 3.73M | 4.03M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -649K | -5.25M | -51.1M | -22.6M | -14.1M | -8.15M | -2.76M | -3.47M | -3.21M | -2.86M |
| Capital Expenditure | 9.00K | 4.49M | 11.1M | 328K | 292K | 12.0K | 17.0K | 60.0K | 65.0K | 84.4K |
| Free Cash Flow | -658K | -9.74M | -62.2M | -22.9M | -14.4M | -8.16M | -2.78M | -3.53M | -3.28M | -2.95M |
| Ratios | ||||||||||
| ROE | -2.7% | -0.6% | -72.4% | -293.1% | -89.2% | -115.4% | -116.2% | -17.2% | -73.8% | -67.7% |
| ROA | -2.6% | -0.6% | -66.6% | -246.1% | -67.2% | -78.4% | -64.1% | -9.3% | -34.5% | -28.4% |
| Net Profit Margin | -45,183.3% | -2.3% | -262.5% | -696.2% | -182.3% | -149.8% | -90.8% | -11.5% | -35.5% | -14.9% |
| Debt to Equity | 0.00x | 0.00x | 0.04x | 0.08x | 0.14x | 0.20x | 0.20x | 0.19x | 0.50x | 0.63x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Elixinol Global Ltd dividends
Elixinol Global Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 1:8 on Dec 2, 2024.
Who owns Elixinol Global Ltd
- Insiders 37.67%
- Institutions 0.00%
- Public & others 62.33%
- Shares outstanding 454M
- Free float 330M
Elixinol Global Ltd company profile
- Company name
- Elixinol Global Ltd
- Ticker
- ELLXF.US
- ISIN
- AU000000EXL4
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- 51 - 53 Riversdale Road, Newtown, VIC, Australia, 3220
- Phone
- 61 2 4044 4585
- Website
- elixinolwellness.com
About Elixinol Global Ltd
Elixinol Wellness Limited, a holding company, produces and sells human nutrition, human wellness, pet wellness, and superfood ingredients in Australia, the Americas, and internationally. The company offers its products under Hemp Foods Australia, Mt Elephant, The Healthy Chef, Soul Foods, Ananda Equine, and Field Day brands. It distributes its products through grocery, wholesale, and e-commerce channels for white label customers, as well as food, beverage, and beauty manufacturers. In addition, the company engages in the manufacture and distribution of hemp-derived cannabidiol (CBD) products. The company was formerly known as Elixinol Global Limited and changed its name to Elixinol Wellness Limited in May 2021. The company was incorporated in 2017 and is based in Newtown, Australia.
Elixinol Global Ltd management
7- Ms. Natalie ButlerCEO & Executive Director
- Mr. Adam DimitropoulosChief Financial Officer
- Mr. Mitchell CostinOperations Director
- Glen ZurcherAccount Director of Investor Relations Department
- Mr. Peter GibsonGeneral Manager of Sales
- Ms. Mariia SkorikovaJoint Company Secretary
- Mr. Tony Di PietroJoint Company Secretary